Program Committee

Jeremy A. Abbate, Vice President & Publisher, Scientific American
Querida Anderson, Editorial Director & Biopharma Expert
Phyllis Barkman Ferrell, Global Head of External Engagement for Alzheimer’s disease & Neurodegeneration, Eli Lilly & Company
Derek Brand, Executive Director, Strategic Partnerships, Columbia Technology Ventures
Sara Jane Demy, CEO & Founder, Demy-Colton
Simone Fishburn, Vice President & Editor in Chief, BioCentury
Walter Greenleaf, Distinguished Visiting Scholar, Stanford University’s MediaX Program
Kimberly Ha, CEO & Founder, KKH Advisors
Mark Kessel, Founding Advisor, Galileo Life Sciences
Tim Opler, Managing Director, Torreya
Art Pappas, Founder & Managing Partner, Pappas Capital
Dennis Purcell, Founder & Senior Advisor, Aisling Capital
Beth Rogozinski, CEO, Signal2Health
Robert J. Schneider, Albert Sabin Professor of Molecular Pathogenesis, NYU School of Medicine
Ajit Singh, Managing Director & General Partner, Artiman Ventures

Scientific Advisory Board

Adam Gazzaley, David Dolby Distinguished Professor of Neurology, Physiology & Psychiatry, UC San Francisco
Walter Greenleaf, Distinguished Visiting Scholar, Stanford University's MediaX Program
Laura Helmuth, Editor in Chief, Scientific American
Christina Jenkins, Venture Partner, Phoenix Venture Partners
Robert J. Schneider, Albert Sabin Professor of Molecular Pathogenesis, NYU School of Medicine
Ralph Snyderman, Chancellor Emeritus, James B. Duke Professor of Medicine, and Director of the Center for Personalized Health Care at Duke University